Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.

Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.

Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.

Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.

Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.

Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.

Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.

David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.

Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.

David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.

Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.

Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.

Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.

Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.

Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.

Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.

Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.

Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.

Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.

Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.

Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.